There has been an explosion of new data from targeted therapy studies since the 2017 publication of ASCO's full clinical practice guidelines regarding systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC). In light of these important updates, the panel of experts responsible for...

Terence T. Sio, MD, MS, associate professor of radiation oncology at the Mayo Clinic and specialist in both X-ray-based and proton radiotherapies, discusses study results comparing the efficacy and safety profiles of the current 60 Gray (Gy) standard-of-care dose for patients with locally advanced non-small...

Long-term data from the KEYNOTE-010 trial showed that 35% of over 1,000 patients with non-small cell lung cancer (NSCLC) who had progressed on chemotherapy and were then treated with pembrolizumab remained alive after 3 years. Patients in this study were randomized to receive immunotherapy with...